FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385803299> ?p ?o ?g. }

• W4385803299 abstract "Background: Methylphenidate, atomoxetine, and Amphetamine are the three most commonly used medications approved by the United States Food and Drug Administration (FDA) for the treatment of attention deficit/hyperactivity disorder (ADHD). However, a comprehensive analysis of their safety profiles across various age groups and genders in real-world contexts has yet to be conducted. In this study, a pharmacovigilance analysis was performed using the FDA Adverse Event Reporting System (FAERS) database to examine differences in adverse events between methylphenidate, atomoxetine, and Amphetamine. Methods: From January 2014 to September 2022, FAERS reports listing Methylphenidate, Dexmethylphenidate, Atomoxetine, Amphetamine, Lisdexamfetamine, Dextroamphetamine, and Methamphetamine as primary suspects were analyzed after removing duplicate reports. We used the standardized Medical Dictionary for Regulatory Activities (MedDRA) query generalized search for adverse events at the preferred term level based on case reports. After filtering duplicate reports, disproportionality analysis was used to detect safety signals according to the proportional reporting ratio (PRR). In order to delve into potential safety concerns, we undertook a two-step analysis of the data. Initially, the data was segmented based on age cohorts: 0-5 years, 6-12 years, 13-18 years, and individuals aged ≥19 years. Following this, after partitioning the data into males and females within the 0-18 years age group, and similarly for those aged ≥19 years, further analysis was conducted. Results: The pharmacovigilance analysis uncovered substantial safety signals in the standardized MedDRA queries. Methylphenidate was associated with dyskinesia (PRR = 21.15), myocardial infarction (PRR = 12.32), and hypertension (PRR = 8.95) in children aged 0-5, 6-12, and 13-18 years, respectively, as well as neonatal exposures via breast milk (PRR = 14.10) in adults aged ≥19 years. Atomoxetine was linked to hostility/aggression (PRR = 15.77), taste and smell disorders (PRR = 6.75), and hostility/aggression (PRR = 6.74) in children aged 0-5, 6-12, and 13-18 years, respectively, as well as hostility/aggression (PRR = 14.00) in adults aged ≥19 years. Amphetamine was associated with psychosis and psychotic disorders (PRR = 16.78), hostility/aggression (PRR = 4.39), and Other ischaemic heart disease (PRR = 10.77) in children aged 0-5 years, 6-12 years, and 13-18 years, respectively, and hostility/aggression in adults aged ≥19 years (PRR = 9.16). Significant and noteworthy adverse event signals were also identified at the preferred term level. Specifically, methylphenidate was associated with myocardial infarction, acute myocardial infarction, coronary artery dissection, electrocardiogram QT prolonged, growth retardation, self-destructive behavior, suicidal ideation, and completed suicide. Atomoxetine was linked to electrocardiogram QT prolonged, growth retardation, and tic. Amphetamine was recorded for coronary artery dissection, suicidal ideation, and completed suicide. It was observed that male patients, including both children and adults, showed a more significant and frequent occurrence of adverse events compared to females, particularly in terms of cardiac disorders. The intensity and quantity of adverse event signals were distinctly different between the two genders, with males having a higher number of signals. All detected safety signals were confirmed using signals obtained from the disproportionality analysis. Conclusion: This pharmacovigilance analysis demonstrated significant variations in the safety profiles of methylphenidate, atomoxetine, and Amphetamine across different age groups and between different genders. Following an in-depth analysis of the FAERS database, we discerned prominent safety signals. Notably, the strength of the signals associated with coronary artery dissection induced by methylphenidate and amphetamine, as well as those related to suicide, demand particular attention. Consequently, it remains imperative to persist in monitoring these medications, assessing the associated risks, and carrying out comparative studies particularly geared towards ADHD drugs." @default.
• W4385803299 created "2023-08-15" @default.
• W4385803299 creator A5003799076 @default.
• W4385803299 creator A5005997387 @default.
• W4385803299 creator A5009041393 @default.
• W4385803299 creator A5010776860 @default.
• W4385803299 creator A5027639672 @default.
• W4385803299 creator A5037989560 @default.
• W4385803299 creator A5066306425 @default.
• W4385803299 creator A5068435349 @default.
• W4385803299 creator A5071001297 @default.
• W4385803299 creator A5072438444 @default.
• W4385803299 date "2023-08-14" @default.
• W4385803299 modified "2023-10-16" @default.
• W4385803299 title "Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system" @default.
• W4385803299 cites W1516056697 @default.
• W4385803299 cites W1851231453 @default.
• W4385803299 cites W1965946834 @default.
• W4385803299 cites W1967573217 @default.
• W4385803299 cites W1973005380 @default.
• W4385803299 cites W1988100739 @default.
• W4385803299 cites W1994733566 @default.
• W4385803299 cites W1997593749 @default.
• W4385803299 cites W1999058928 @default.
• W4385803299 cites W1999066126 @default.
• W4385803299 cites W2020837599 @default.
• W4385803299 cites W2035423701 @default.
• W4385803299 cites W2036610559 @default.
• W4385803299 cites W2038642695 @default.
• W4385803299 cites W2042460577 @default.
• W4385803299 cites W2045288514 @default.
• W4385803299 cites W2050111430 @default.
• W4385803299 cites W2060809132 @default.
• W4385803299 cites W2064514267 @default.
• W4385803299 cites W2082384177 @default.
• W4385803299 cites W2085752173 @default.
• W4385803299 cites W2095465504 @default.
• W4385803299 cites W2107516065 @default.
• W4385803299 cites W2108571276 @default.
• W4385803299 cites W2122860734 @default.
• W4385803299 cites W2124380553 @default.
• W4385803299 cites W2130261817 @default.
• W4385803299 cites W2131308754 @default.
• W4385803299 cites W2137706707 @default.
• W4385803299 cites W2142011448 @default.
• W4385803299 cites W2143291772 @default.
• W4385803299 cites W2147477690 @default.
• W4385803299 cites W2149485684 @default.
• W4385803299 cites W2154426538 @default.
• W4385803299 cites W2162012775 @default.
• W4385803299 cites W2169873461 @default.
• W4385803299 cites W2408887111 @default.
• W4385803299 cites W2419318801 @default.
• W4385803299 cites W2560606377 @default.
• W4385803299 cites W2565298673 @default.
• W4385803299 cites W2568798765 @default.
• W4385803299 cites W2763907737 @default.
• W4385803299 cites W2767901467 @default.
• W4385803299 cites W2782999578 @default.
• W4385803299 cites W2791978982 @default.
• W4385803299 cites W2802746085 @default.
• W4385803299 cites W2888169867 @default.
• W4385803299 cites W2889542606 @default.
• W4385803299 cites W2896939971 @default.
• W4385803299 cites W2950666577 @default.
• W4385803299 cites W2976851556 @default.
• W4385803299 cites W298123630 @default.
• W4385803299 cites W2996261837 @default.
• W4385803299 cites W3047276678 @default.
• W4385803299 cites W3087626112 @default.
• W4385803299 cites W3113113850 @default.
• W4385803299 cites W3127059765 @default.
• W4385803299 cites W3147692960 @default.
• W4385803299 cites W3154360409 @default.
• W4385803299 cites W4213383170 @default.
• W4385803299 cites W4293124475 @default.
• W4385803299 cites W4296031308 @default.
• W4385803299 cites W821578762 @default.
• W4385803299 cites W952824133 @default.
• W4385803299 doi "https://doi.org/10.3389/fphar.2023.1208456" @default.
• W4385803299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37645441" @default.
• W4385803299 hasPublicationYear "2023" @default.
• W4385803299 type Work @default.
• W4385803299 citedByCount "0" @default.
• W4385803299 crossrefType "journal-article" @default.
• W4385803299 hasAuthorship W4385803299A5003799076 @default.
• W4385803299 hasAuthorship W4385803299A5005997387 @default.
• W4385803299 hasAuthorship W4385803299A5009041393 @default.
• W4385803299 hasAuthorship W4385803299A5010776860 @default.
• W4385803299 hasAuthorship W4385803299A5027639672 @default.
• W4385803299 hasAuthorship W4385803299A5037989560 @default.
• W4385803299 hasAuthorship W4385803299A5066306425 @default.
• W4385803299 hasAuthorship W4385803299A5068435349 @default.
• W4385803299 hasAuthorship W4385803299A5071001297 @default.
• W4385803299 hasAuthorship W4385803299A5072438444 @default.
• W4385803299 hasBestOaLocation W43858032991 @default.
• W4385803299 hasConcept C118552586 @default.
• W4385803299 hasConcept C126322002 @default.
• W4385803299 hasConcept C197934379 @default.
• W4385803299 hasConcept C199475168 @default.

• next